L-Arginine and Sickle Cell Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

October 31, 2009

Conditions
Sickle Cell Disease
Interventions
DRUG

L-arginine

L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.

DRUG

Placebo

Mannitol was administered orally at a dose of 01 g/kg/day for six months.

Trial Locations (1)

90035-001

Hospital de Clínicas de Porto Alegre, Porto Alegre

All Listed Sponsors
collaborator

Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)

UNKNOWN

collaborator

Associação de Amigos da Hematologia (HEMOAMIGOS)

UNKNOWN

collaborator

Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine)

UNKNOWN

lead

Hospital de Clinicas de Porto Alegre

OTHER

NCT01142219 - L-Arginine and Sickle Cell Disease | Biotech Hunter | Biotech Hunter